BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.

Read the original:
HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused structure-based drug design (SBDD) and development, is pleased to announce it has won Licensing Deal of the Year and Executive of the Year at the first Informa Pharma Intelligence Awards Japan held yesterday in Tokyo.

Continued here:
Sosei Heptares Wins Licensing Deal of the Year and Executive of the Year at the Inaugural Informa Pharma Intelligence Awards Japan

Basel, September 2, 2022 — Novartis today announced it will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress and the 15th International Symposium on Sjögren’s Syndrome (ISSS), both occurring September 7–10, 2022. A total of 37 abstracts will be shared across both meetings, spanning hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), Sjögren’s syndrome, axial spondyloarthritis, and psoriasis.

Read more here:
Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses

DXS INTERNATIONAL PLC

More:
Trading Update

BASEL, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and Uneek Mehra, Chief Financial and Business Officer, will participate in the following upcoming investor conferences:

Read the original:
Myovant Sciences to Participate at Upcoming Investor Conferences

Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments

Read more:
Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins

MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates:

Continued here:
Genetic Technologies Provides Update on US Operations and Payer Engagement

MENLO PARK, Calif. and SINGAPORE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give an in-person company presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:30 am ET. The conference will be held from September 12 to 14, 2022, virtually and in-person at the Lotte New York Palace Hotel.

Link:
ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON and LAUSANNE, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today Chief Executive Officer, Dr. Jurgi Camblong and Chief Financial Officer, Ross Muken will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, at 8:45 a.m. EDT.

See the original post:
SOPHiA GENETICS to Participate in Fireside Chat at 20th Annual Morgan Stanley Global Healthcare Conference

SEATTLE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Read more from the original source:
Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference

SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program, will be presenting data from a planned two-year interim analysis from the ACROBAT Advance open label extension (OLE) study at the 35th Brazilian Congress of Endocrinology and Metabolism (CBEM) being held in São Paulo, Brazil from September 3-7, 2022.

View original post here:
New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and...

SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

More here:
Fate Therapeutics to Participate at Upcoming September Investor Conferences

WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Neha Krishnamohan has been appointed to the Arcutis Board of Directors and as a member of the audit committee. Following the appointment, the Board will be composed of 10 directors.

Visit link:
Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors

CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). The IND application supports a Phase 1/2a clinical trial of IMM-1-104, an oral once daily small molecule in development for the treatment of advanced RAS mutant solid tumors. In contrast to the narrow approach of targeting specific mutations such as KRAS-G12C, IMM-1-104 is a third generation MEK inhibitor designed for broad pan-RAS activity as well as activity in other MAPK-activated tumors. Based on preclinical data to date, IMM-1-104 has demonstrated robust single-agent anti-tumor activity across a broad range of in vitro and in vivo tumor models driven by MAPK pathway activation events. This includes animal models of KRAS mutant pancreatic cancer, NRAS mutant melanoma, KRAS mutant colorectal cancer, and KRAS mutant lung cancer, regardless of the specific mutation upstream of MEK that drives activation of the MAPK pathway, and all while maintaining a well-tolerated safety profile in such models.

Read more:
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year ended June 30, 2022. The Company has filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange Commission.

Follow this link:
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

Company also retains B2i Digital to enhance engagement with the investor community

Original post:
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE2 SEPTEMBER 2022 at 17.30 EEST

View post:
Prosecutor appealed the district court's decision to dismiss the charges pressed against a member of Orion's Board of Directors for a suspected...

COPENHAGEN, Denmark, September 2, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the dosing of the first subject in the Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.

The rest is here:
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Montrouge, France, September 2, 2022

Continue reading here:
DBV Technologies to Present at Upcoming Investor Conferences

Leuven, BELGIUM, Boston, MA, US – September 2, 2022 – CET 10:30PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has amended its mandatory convertible bonds issuance and subscription agreement announced on April 6, 2021 (“funding program”) with the Negma Group, a financial institution focused on supporting growth and capturing value through a multi-strategy approach. The proceeds will be devoted to Oxurion’s KALAHARI Phase 2, Part B clinical trial. The trial is currently underway and is evaluating THR-149, its novel therapeutic for second line therapy, against market leader aflibercept in the treatment of diabetic macular edema (DME) for the 40-50% of DME patients that get suboptimal response to standard of care anti-VEGF therapy, with top-line data expected mid next year.

Read more:
Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding